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In spite of complex interactions between 
drugs and dietary supplements, which increase 
with the number of them taken, the medical, or 
on occasions, the patient’s judgment tends to be 
fast and dichotomous. Many contexts of clinical 
practice do not have scientific evidence derived 
from randomized clinical trials and action is based 
on physiopathological or simply epidemiological 
analysis, and in worst cases personal or common 
beliefs.
Karny-Rahkovich et al’s. study [1] evaluated 
the use of dietary supplements in 149 patients 
with cardiovascular (CV) disease who consulted 
an Internal Medicine Ward and an Emergency 
Cardiology Clinic. Despite being a small sample, 
high use of dietary supplements (45%) associated 
with older age, female sex and a physical activity 
routine was observed. They also identified 16 po-
tential interactions between the prescribed medical 
treatment and dietary supplements. It would have 
been interesting to compare the rate of use of 
dietary supplements with a control group without 
CV disease. The study repeats the finding that 
people who carry out physical activity refer greater 
consumption of potentially harmful supplements of 
unproven usefulness. The work details the poten-
tially dangerous interactions between drugs and 
dietary supplements, although the clinical impact 
is not fully known [1].
In this sense, the association of elevated levels 
of homocysteine with higher CV risk and the possi-
bility of its descent through the use of folic acid lead 
many our colleagues to indicate it systematically. 
The subsequent randomized studies have shown 
that the administration of folic acid to reduce levels 
of homocysteine not only does not reduce CV risk, 
they also showed that the administration of vitamin 
B caused an increase in mortality [2].
The association between vitamin E intake and 
lower incidence of CV events was demonstrated 
following an epidemiological prospective observa-
tional study conducted on nurses. This finding gen-
erated a large increase in the consumption of anti-
oxidants such as vitamin E, even among American 
doctors. Subsequently, several randomized clinical 
trials on large cohorts highlighted the absence of 
any protective effect on vascular events and even 
a higher risk if used in high doses [3].
In spite of the benefits of vitamin C on en-
dothelial function and the popular acceptance of its 
benefits, the systematic administration of a vitamin 
complex (600 mg vitamin E, 250 mg vitamin C, and 
20 mg beta-carotene daily) in a multicenter study 
dismissed the improvement in the prognosis, yet 
not causing higher rate of adverse effects [4].
Finally, a meta-analysis that included 68 stud-
ies showed that the administration of antioxidants 
was associated with an increase in mortality: beta- 
-carotene (vitamin B) — RR 1.07 (95% CI 1.02–
–1.11), vitamin A — RR 1.16 (95% CI 1.1–1.24), 
vitamin E — RR 1.04 (95% CI 1.01–1.07) with no 
defined adverse effects and no clear benefits with 
vitamin C or selenium supplements [5].
The evidence showing CV benefit from the 
use of vitamin D is not conclusive in spite of the 
fact that in epidemiological studies the reduction 
in vitamin D levels has been linked to an increased 
risk of developing CV disease. Vitamin D3 seems 
to decrease the mortality in the elderly, vitamin 
D2, alfacalcidol and calcitriol do not have statis-
tically significant effects on mortality, vitamin 
D3 combined with calcium increases the rate of 
nephrolithiasis and alfacalcidol as well as calcitriol 
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increase hypercalcemia. Given the biases of the 
published studies, the dropout of patients included 
in the report of mortality, and the weakness of the 
available evidence, large cohort randomized stud-
ies are needed to compare the administration of 
vitamin D vs. placebo [6].
Despite the use of dietary supplements, there 
are no studies demonstrating their use in the 
primary prevention of CV disease or cancer nor 
is there enough information to analyze the clini-
cal impact of their individual interaction in daily 
practice [7].
The available evidence establishes that the 
utility of dietary supplements is part of the belief 
and expectations of the patient and is sometimes 
a desire of the pharmaceutical industry. Given that 
the clinical benefits have not been tested, it is best 
not to prescribe them, avoid erroneous medical 
practices and in the best of cases to encourage 
a deeper discussion in the community and a more 
cautious approach in doctors and patients.
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